$ARDX stock is up by 55% since it lobbied Congress in early Feb on Medicare
On February 1st, after Ardelyx spent $340k lobbying Congress on issues related to Medicare ESRD benefits & chronic kidney disease management, our Lobbying Spending Growth Strategy went long on $ARDX. The stock has soared nearly 55% since.
